Tepezza (teprotumumab) is given as a series of eight intravenous infusions over roughly 21 weeks. The first infusion is dosed at 10 mg/kg of body weight, and the remaining seven are dosed at 20 mg/kg, with each infusion spaced three weeks apart. That schedule sounds straightforward on paper, but real-world completion rates, side-effect management, metabolic monitoring, and the possibility of relapse all shape how dosing actually plays out for most patients.
The Standard Eight-Infusion Course
Tepezza is the only FDA-approved medication specifically for thyroid eye disease (TED), the autoimmune condition that causes the tissues behind and around the eyes to swell, pushing the eyeballs forward (proptosis) and sometimes causing double vision. The drug works by blocking the insulin-like growth factor-1 receptor (IGF-1R), which is overactive on the orbital fibroblasts driving the inflammation and tissue expansion behind the eyes.1PubMed Central. Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review
The dosing protocol approved by the FDA calls for a total of eight infusions administered at an infusion center. Infusion one uses the lower 10 mg/kg dose, which serves as a loading step. Three weeks later, the dose doubles to 20 mg/kg and stays there for infusions two through eight. Each infusion is delivered intravenously over about 60 to 90 minutes, and patients typically remain under observation for a short period afterward. Assuming no delays, the full course takes about 21 weeks from the first infusion to the last, with clinical assessments usually happening around week 24.
The drug has a long elimination half-life of about 20 days, which is why the three-week spacing works: serum concentrations stay high enough between infusions to maintain IGF-1R blockade throughout the treatment course.2PubMed Central. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease The weight-based dosing means that a patient weighing 70 kg receives 700 mg at the first infusion and 1,400 mg at each subsequent one, while someone at 100 kg receives 1,000 mg and then 2,000 mg. There is no dose cap published in the prescribing information, and no routine dose adjustments for age or mild organ impairment.
What Happens During an Infusion Visit
Tepezza infusions are given at dedicated infusion centers or hospital outpatient settings. Because the drug is a monoclonal antibody delivered intravenously, patients need IV access for each visit. Infusion-related reactions can occur, so staff monitor vital signs during and after the drip. Common reactions tend to be mild and include muscle spasms, nausea, and fatigue. Infusion center guidelines generally recommend watching patients for at least 30 minutes after the infusion ends before discharge.3PubMed Central. Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects
From a practical standpoint, each visit can take two to three hours when you factor in check-in, IV setup, the infusion itself, and the observation window. Over eight visits across five months or so, that is a meaningful time commitment, and coordinating insurance pre-authorizations for each infusion adds another layer of logistics.
Real-World Completion Rates
Clinical trials enroll motivated patients who are closely monitored, so completion rates in those settings tend to be high. Real-world data tell a different story. A large cohort study using linked registry and claims data found that only about 65% of patients who started Tepezza completed all eight infusions. The median time to finish the course was five months, which lines up with the expected schedule. Among those who stopped early, the average number of infusions received was four, and the most common point of dropout was right before the seventh infusion.4PubMed Central. Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database
The reasons for early discontinuation range from side effects to insurance issues to logistical challenges. In a multicenter adverse-event study, about 12% of patients stopped treatment specifically because of side effects, with hearing loss, inflammatory bowel disease flares, hyperglycemia, and muscle spasms among the cited reasons.5PubMed Central. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study The spike in dropout near infusion seven is curious. It may reflect a mix of patients who feel they have already gotten enough benefit, patients whose side effects accumulate late in the course, and patients running into insurance or financial walls as the treatment total climbs.
Hearing Symptoms and How They Affect the Dosing Decision
The side effect that gets the most attention during Tepezza treatment is hearing-related. In one analysis of 28 patients, nearly half reported some kind of hearing symptom, most commonly a plugged-ear sensation, muffled hearing, or autophony (hearing your own voice unusually loudly). These symptoms appeared after an average of about 3.6 infusions, which means they tend to crop up roughly a third of the way through the course.6PubMed Central. Hearing Loss and Teprotumumab
Among those with hearing complaints in that study, about 23% had objectively documented sensorineural hearing loss on audiometry, and those losses did not significantly improve in the months after stopping the drug. That persistence is what makes hearing changes a particularly difficult dosing dilemma. If a patient develops muffled hearing after infusion three or four, the treating team has to weigh the benefit of completing the course against the risk of worsening or permanent hearing damage. There is no formal dose-reduction protocol for hearing symptoms; the decision is typically to pause or discontinue treatment entirely.
Because IGF-1R is expressed in the inner ear, the hearing effects are thought to be an on-target consequence of the drug’s mechanism rather than an allergic or idiosyncratic reaction. That makes them somewhat predictable in timing but difficult to prevent. Many specialists now recommend baseline audiometry before the first infusion and repeat testing midway through the course so that subclinical changes can be caught early.
Blood Sugar Monitoring During Treatment
IGF-1R signaling is closely tied to insulin signaling, so it is not surprising that blocking IGF-1R can push blood sugar upward. In the pooled clinical trial data, teprotumumab-treated patients saw an average increase of 0.22% in HbA1c from baseline to week 24, compared with 0.04% in the placebo group. Fasting glucose tended to rise after the second or third infusion and then stabilize. Most hyperglycemic episodes occurred in patients who already had prediabetes or diabetes at baseline, and they were generally controlled with adjustments to diabetes medications.7PubMed. Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials
Those trial-level numbers sound reassuring, but longer-term follow-up paints a more cautious picture. A large multinational cohort study that followed patients for up to five years after treatment found that Tepezza-treated patients had roughly double the risk of developing prediabetes compared with matched controls, with 24% of treated patients affected versus 10% of controls. The risk of new-onset diabetes was also about twice as high, and treated patients were more likely to need new diabetes medications over the follow-up period.8PubMed. Teprotumumab-Associated Hyperglycemia: A Large-Scale Multinational Cohort Study
For patients with normal blood sugar at baseline, the short-term metabolic bump during the infusion course is usually modest and self-resolving. But if you already have prediabetes or diabetes, your endocrinologist will likely want to monitor fasting glucose and HbA1c closely, especially around infusions two through four when the glucose shift tends to kick in. In rare cases, hyperglycemia severe enough to warrant stopping treatment has been reported.
How Well the Benefits Last After Treatment Ends
A natural question after finishing a five-month infusion course is whether the improvements stick. In the OPTIC-X extension study, responses were well-maintained: among patients who responded to the initial course, roughly 91% maintained their proptosis improvement, 95% kept their low clinical activity scores, and about 86% maintained their diplopia response at a follow-up point of 48 weeks after the last infusion.9PubMed. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study
That extension study followed a carefully selected trial population, though. A smaller, independent study tracking 21 patients in real-world practice found higher rates of regression. Of 17 initial responders, nearly half experienced reactivation of their TED, and a few had isolated proptosis regression without full disease flare. The average time to regression was about 12 months, with a wide range from 2 to over 22 months. Overall, only a third of patients in that cohort maintained their response throughout the entire study period.10American Journal of Ophthalmology. Recurrence and Reactivation Rates After Teprotumumab Therapy for Active Thyroid Eye Disease
The discrepancy between the extension trial and real-world follow-up is worth understanding. Trial populations had stricter enrollment criteria, and disease characteristics at baseline can heavily influence who holds onto their response. Patients with longstanding or chronic TED, unstable thyroid function, or ongoing smoking may be at higher risk for relapse after treatment ends.
Retreatment With a Second Course
When disease reactivates after the first course of Tepezza, a second round of eight infusions using the same dosing protocol is sometimes considered. The OPTIC-X trial included a retreatment arm for patients who initially received placebo or who flared after responding, and it showed that the drug works on a second pass. Formal retreatment guidelines are still evolving, though, because the long-term safety of repeated courses is less well characterized.
Case reports have documented successful retreatment. One published case of refractory TED described a patient who received a full second eight-infusion course after the first did not adequately control symptoms. The second course produced a sustained improvement, including a 5 mm proptosis reduction in one eye and 2 mm in the other, with only mild side effects such as nail changes, brief muscle cramps, and mild fatigue over 13 months of follow-up.11AACE Endocrinology and Diabetes. Tepezza, Take Two: A Case Report of Second Course of Teprotumumab Beyond Standard Protocol for Refractory Thyroid Eye Disease
The open question for retreatment is whether the benefit-risk balance shifts. Hearing symptoms and metabolic changes may compound across courses, especially for patients who already experienced them the first time around. Most experts recommend a thorough discussion of risks before starting a second course, with updated audiometry and metabolic workup at baseline.
Tepezza for Chronic and Long-Duration TED
The original Tepezza trials enrolled patients with relatively recent-onset, active TED. The drug’s approval reflects that population. But a significant portion of TED patients have long-duration or low-activity disease, meaning their eyes have already settled into a stable but disfigured or functionally impaired state, with proptosis and sometimes diplopia but without the acute inflammation seen in early TED.
A dedicated trial in this population found that Tepezza still works, though the magnitude of benefit is somewhat smaller. Patients with chronic TED treated with teprotumumab saw an average proptosis reduction of about 2.4 mm at 24 weeks, compared with about 0.9 mm in the placebo group. About 62% of treated patients met the proptosis response threshold, versus 25% on placebo.12PubMed Central. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity The dosing schedule in this trial was the same standard eight-infusion protocol, meaning the drug does not need to be given differently for chronic disease. The improvements in proptosis and diplopia, along with quality-of-life gains, give patients with longstanding TED an option that previously did not exist short of surgery.13PubMed Central. Teprotumumab (Tepezza) for Thyroid Eye Disease
How Tepezza Compares to IV Steroids
Before Tepezza, the standard medical treatment for moderate-to-severe active TED was intravenous methylprednisolone (IVMP), a course of high-dose steroid infusions given weekly or biweekly. Steroids reduce inflammation broadly, but they do not target the specific orbital fibroblast pathway the way Tepezza does. A systematic review comparing the two treatments found that teprotumumab generally produced better outcomes than conventional IVMP.14PubMed Central. Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review
A meta-analysis with matching-adjusted indirect comparison put numbers to the difference in quality of life. Patients receiving Tepezza showed a meaningful improvement in overall Graves’ ophthalmopathy quality-of-life scores compared with those receiving moderate-dose IVMP, with gains in both the appearance and visual-function domains. Strikingly, when IVMP was compared with placebo in the same analysis, there was no statistically significant quality-of-life advantage, suggesting that steroids help with inflammation but may not move the needle much on the outcomes patients care about most.15Journal of the Endocrine Society. Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison
The tradeoff is cost and access. IV steroids are inexpensive and available everywhere. Tepezza is one of the most expensive drugs in ophthalmology, with a full eight-infusion course running into six figures in the United States. That price tag, along with the fact that Tepezza is not yet widely available outside the US, remains a significant barrier to global adoption.16PubMed Central. Teprotumumab in thyroid eye disease: wonder drug or great divider? For patients with access and insurance coverage, the clinical advantages of Tepezza over steroids are substantial. For those without, IVMP remains the backbone of medical treatment.
Who Should Not Receive Tepezza
Tepezza is approved for adults. Because IGF-1R signaling plays a critical role in growth plate development, the drug should not be given to children who have not finished puberty. An expert consensus panel was explicit on this point, recommending that teprotumumab not be prescribed to prepubertal children until safety data in that age group become available.17PubMed Central. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach The concern is not just theoretical: blocking IGF-1R in growing bones could plausibly stunt linear growth.
Pregnancy is another contraindication. IGF-1R is important in fetal development, and animal data suggest potential harm. Women of childbearing age are advised to use effective contraception during treatment and for a period afterward, given the drug’s long half-life.
Patients with active inflammatory bowel disease (IBD) warrant extra caution. IBD flares were among the reasons patients discontinued treatment in multicenter safety data, and IGF-1R has roles in gut mucosal biology that are not fully understood. The drug is not absolutely contraindicated in IBD, but the decision to proceed requires careful discussion between the patient, their gastroenterologist, and their ophthalmologist.
The Mechanism Behind the Dosing Logic
The reason Tepezza uses a lower first dose followed by higher maintenance doses is standard monoclonal antibody pharmacology: the loading dose begins saturating the target receptor while the body adjusts to the foreign protein, and then the higher dose maintains therapeutic drug levels given the drug’s clearance rate. Tepezza’s clearance is low at about 0.33 liters per day, and its volume of distribution is small, mostly confined to the bloodstream and the target tissue. That pharmacokinetic profile supports the every-three-week schedule without requiring more frequent dosing.18PubMed Central. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease
At the cellular level, Tepezza blocks a signaling partnership between the IGF-1 receptor and the TSH receptor on orbital fibroblasts. When thyroid-stimulating antibodies (the autoantibodies behind Graves’ disease) activate the TSH receptor, part of that activation leaks through to IGF-1R via receptor crosstalk. Tepezza shuts down the IGF-1R-dependent arm of that signaling. Research has shown that the drug fully blocks stimulation at lower autoantibody levels but only partially blocks it when autoantibody concentrations are very high, because the TSH receptor can also signal independently of IGF-1R at higher stimulation levels.19The Journal of Clinical Endocrinology & Metabolism. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease This helps explain why some patients with very high antibody titers or aggressive disease may have a less complete response and why the drug works best when used in the context of overall thyroid disease management.
Practical Tips for Patients Going Through the Course
If you are starting or planning a Tepezza infusion course, a few practical considerations can smooth the process. First, get a baseline audiogram before infusion one. If your hearing is normal at baseline and you develop subtle changes midcourse, that documented starting point becomes invaluable. Second, if you have any history of prediabetes or diabetes, coordinate with your endocrinologist to set up a glucose monitoring plan. Fasting glucose checks around infusions two and three, when the metabolic effect tends to appear, can catch early shifts before they spiral.20PubMed. Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials
Third, plan your schedule realistically. Eight infusion visits over five months, each taking a chunk of your day, with possible fatigue in the day or two afterward, is a logistical commitment. Some patients arrange infusions on Fridays so they have the weekend to recover. Fourth, keep in mind that most of the eye improvement tends to be visible by infusion four or five, but the full course is designed to consolidate and deepen that response. Dropping out early because you feel better at the halfway mark may leave benefit on the table and could increase the risk of relapse.
Finally, the cost conversation should happen early. Your specialist’s office likely has experience navigating prior authorization, and the manufacturer offers a patient assistance program for qualifying individuals. Given that a third of patients in real-world data do not finish the course, financial and logistical hurdles are worth addressing before the first drip starts rather than after infusion three when insurance balks at covering number four.21PubMed Central. Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database